✦ LIBER ✦
Late-Breaking Abstract 5: Results from a 2nd interim OS analysis in OCEANS: A randomized phase 3 trial of gemcitabine (G), carboplatin (C) and bevacizumab (BV) followed by BV to disease progression in patients with platinum-sensitive recurrent epithelial ovarian (OC), primary peritoneal (PPC), or fallopian tube cancer (FTC)
✍ Scribed by C. Aghajanian; S. Blank; B. Goff; P. Judson; L. Nycum; M. Sovak; J. Yi; A. Husain
- Book ID
- 113964124
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 42 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0090-8258
No coin nor oath required. For personal study only.